These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37950758)

  • 61. Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.
    Giannisis A; Al-Grety A; Carlsson H; Howell JC; Hu WT; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2023 Jul; 15(1):119. PubMed ID: 37400888
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition.
    Hu Q; Shi M; Li Y; Zhao X
    BMC Neurol; 2024 Jul; 24(1):236. PubMed ID: 38971733
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.
    Zerr I; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Ferrer I; Riggert J; Zetterberg H; Blennow K; Llorens F
    Alzheimers Res Ther; 2021 Apr; 13(1):86. PubMed ID: 33883011
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease.
    Andersson E; Janelidze S; Lampinen B; Nilsson M; Leuzy A; Stomrud E; Blennow K; Zetterberg H; Hansson O
    Neurobiol Aging; 2020 Nov; 95():143-153. PubMed ID: 32810755
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Diagnostic Performance of Cerebrospinal Fluid Neurofilament Light Chain and Soluble Amyloid-β Protein Precursor β in the Subcortical Small Vessel Type of Dementia.
    Axelsson Andrén E; Kettunen P; Bjerke M; Rolstad S; Zetterberg H; Blennow K; Wallin A; Svensson J
    J Alzheimers Dis; 2023; 96(4):1515-1528. PubMed ID: 37980667
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serial Cerebrospinal Fluid Sampling Reveals Trajectories of Potential Synaptic Biomarkers in Early Stages of Alzheimer's Disease.
    Duits FH; Nilsson J; Zetterberg H; Blennow K; van der Flier WM; Teunissen CE; Brinkmalm A
    J Alzheimers Dis; 2024; 100(s1):S103-S114. PubMed ID: 39121126
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
    Álvarez-Sánchez L; Peña-Bautista C; Ferré-González L; Balaguer A; Baquero M; Casanova-Estruch B; Cháfer-Pericás C
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674742
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics.
    Behzadi A; Pujol-Calderón F; Tjust AE; Wuolikainen A; Höglund K; Forsberg K; Portelius E; Blennow K; Zetterberg H; Andersen PM
    Sci Rep; 2021 Nov; 11(1):22128. PubMed ID: 34764380
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
    Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K
    Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
    Dhiman K; Gupta VB; Villemagne VL; Eratne D; Graham PL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Hone E; Blennow K; Zetterberg H; Martins RN
    Alzheimers Dement (Amst); 2020; 12(1):e12005. PubMed ID: 32211500
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study.
    Dhiman K; Villemagne VL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Blennow K; Zetterberg H; Martins RN; Gupta V
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625782
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.
    Meeker KL; Butt OH; Gordon BA; Fagan AM; Schindler SE; Morris JC; Benzinger TLS; Ances BM
    Neurobiol Dis; 2022 May; 166():105662. PubMed ID: 35167933
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia.
    Silva-Spínola A; Lima M; Leitão MJ; Durães J; Tábuas-Pereira M; Almeida MR; Santana I; Baldeiras I
    Eur J Neurol; 2022 Jan; 29(1):36-46. PubMed ID: 34375485
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Blood TDP-43 Combined with Demographics Information Predicts Dementia Occurrence in Community Non-Dementia Elderly.
    Sun L; Li W; Yue L; Xiao S
    J Alzheimers Dis; 2021; 79(1):301-309. PubMed ID: 33252084
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
    Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
    Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis.
    Fan Z; Liu X; Liu J; Chen C; Zhou M
    J Integr Neurosci; 2023 Jun; 22(4):85. PubMed ID: 37519166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.